Top

Strahlentherapie und Onkologie

Published in:

01-05-2014 | Original article

The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines

Authors: G. Heiduschka, C. Lill, S. Schneider, R. Seemann, G. Kornek, R. Schmid, U. Kotowski, D. Thurnher, M. D.

Published in: Strahlentherapie und Onkologie | Issue 5/2014

Abstract

Background

Integrins are highly attractive targets in oncology due to their involvement in angiogenesis in a wide spectrum of cancer entities. Among several integrin inhibitors under clinical evaluation, cilengitide is the most promising compound. However, little is known about the cellular processes induced during cilengitide therapy in combination with irradiation and cisplatin in head and neck squamous cell carcinoma (HNSCC).

Materials and methods

The cytostatic effect of cilengitide was assessed by proliferation assay in the three HNSCC cell lines SCC25, FaDu and CAL27. Combination experiments with cisplatin and irradiation were performed. Possible synergistic effects were calculated in combination index (CI) analyses. Colony forming inhibition was investigated in clonogenic assays. Real-time PCR arrays were used to evaluate target protein gene expression patterns. Flow cytometry was used to detect apoptosis.

Results

Used alone, cilengitide has only minor cytotoxic effects in HNSCC cell lines. However, combination with cisplatin resulted in synergistic growth inhibition in all three cell lines. Irradiation showed synergism in short-term experiments and in colony forming assays, an additive effect was detected. Real-time PCR assay detected downregulation of the antiapoptotic protein Bcl-2 after exposure of cells to cilengitide.

Conclusion

Cilengitide in combination with cisplatin and irradiation may be a feasible option for the treatment of patients with head and neck cancer. However, further investigations are required to understand the exact mechanism that leads to synergistic cytotoxicity.

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Erpolat OP, Gocun PU, Akmansu M et al (2012) Hohe Expression von nukleärem Survivin und Aurora-B als prädiktive Marker für das schlechte Gesamtüberleben bei Patienten mit Plattenepithelkarzinomen der Kopf- und Halsregion. Strahlenther Onkol 188:248–254PubMedCrossRef

Maurer J, Hipp M, Schäfer C, Kölbl O (2011) Dysphagia. Strahlenther Onkol 187:744–749PubMedCrossRef

Denaro N, Russi EG, Colantonio I et al (2012) The role of antiangiogenic agents in the treatment of head and neck cancer. The International Society for Cellular 83:108–116

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRef

Hagen tenTLM, Seynhaeve ALB, Wiel-Ambagtsheer GAdeetal (2012) The αVb3/αVb5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. Int J Cancer 132:2694–2704PubMedCrossRef

Brooks PC, Montgomery AM, Rosenfeld M et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164PubMedCrossRef

Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571PubMedCrossRef

Brooks PC, Strömblad S, Klemke R et al (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822PubMedCentralPubMedCrossRef

10.

Beer AJ, Grosu AL, Carlsen J et al (2007) [18F]Galacto-RGD positron emission tomography for imaging of v 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6610–6616PubMedCrossRef

11.

Fabricius E-M (2010) Immunohistochemical analysis of integrins αvb3, αvb5 and α5b1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med 2:9–19PubMedCentralPubMed

12.

Reardon DA, Nabors LB, Stupp R, Mikkelsen T (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17:1225–1235PubMedCentralPubMedCrossRef

13.

MacDonald TJ, Stewart CF, Kocak M et al (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26:919–924PubMedCrossRef

14.

Stupp R, Hegi ME, Neyns B et al (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712–2718PubMedCrossRef

15.

Gilbert MR, Kuhn J, Lamborn KR et al (2011) Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106:147–153PubMedCrossRef

16.

Nabors LB, Mikkelsen T, Hegi ME et al (2012) A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118:5601–5607PubMedCentralPubMedCrossRef

17.

Bradley DA, Daignault S, Ryan CJ et al (2010) Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs 29:1432–1440PubMedCentralPubMedCrossRef

18.

Alva A, Slovin S, Daignault S et al (2010) Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 30(2):749–757PubMedCentralPubMedCrossRef

19.

Kim KB, Prieto V, Joseph RW et al (2012) A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 22:294–301PubMedCrossRef

20.

Friess H, Langrehr JM, Oettle H et al (2006) A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6:285PubMedCentralPubMedCrossRef

21.

Raguse J-D, Gath HJ, Bier J et al (2004) Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40:228–230PubMedCrossRef

22.

Vermorken JB, Guigay J, Mesia R et al (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104:1691–1696PubMedCentralPubMedCrossRef

23.

Vormittag L, Lemaire C, Radonjic D et al (2012) Re-irradiation kombiniert mit Capecitabin bei lokal rezidivierten Plattenepithelkarzinomen der Kopf-Hals-Region. Strahlenther Onkol 188:235–242PubMedCrossRef

24.

Kotowski U, Heiduschka G, Brunner M et al (2011) Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane. Strahlenther Onkol 187:575–580PubMedCrossRef

25.

Heiduschka G, Erovic BM, Vormittag L et al (2009) 7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 135:261–267PubMedCrossRef

26.

Franken NAP, Rodermond HM, Stap J et al (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319PubMedCrossRef

27.

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55PubMedCrossRef

28.

Serono EMD: Phase III trial of cilengitide did not meet primary endpoint in patients with newly diagnosed glioblastoma [Internet] (2013) http://www.emdserono.com. http://www.emdserono.com/cmg.emdserono_us/en/images/EMD%20Serono%20CENTRICResults_FINAL2-25-13_tcm115_105637.pdf. Accessed 13 February 2014

29.

Vermorken JB (2012) Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the ADVANTAGE phase II trial. Abstract No. 5516; 2012 ASCO Annual Meeting

30.

Mikkelsen T, Brodie C, Finniss S et al (2008) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124:2719–2727CrossRef

31.

Kim Y-H, Lee JK, Kim B et al (2013) Combination therapy of cilengitide with belotecan against experimental glioblastoma. Int J Cancer 133:749–756

32.

Burke PA, DeNardo SJ, Miers LA et al (2002) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263–4272PubMed

33.

Azmi AS, Wang Z, Philip PA et al (2011) Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 16:59–70PubMedCentralPubMedCrossRef

34.

Choi B-H, Yoon HS (2011) FKBP38-Bcl-2 interaction: a novel link to chemoresistance. Curr Opin Pharmacol 11:354–359PubMedCrossRef

35.

Yamada S, Bu X-Y, Khankaldyyan V et al (2006) Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59:1304–1312PubMedCrossRef

36.

Albert JM, Cao C, Geng L et al (2006) Integrin αvb3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65:1536–1543PubMedCrossRef

37.

Lomonaco SL, Finniss S, Xiang C et al (2011) Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro Oncol 13:857–865PubMedCentralPubMedCrossRef

Title: The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines
Authors: G. Heiduschka
C. Lill
S. Schneider
R. Seemann
G. Kornek
R. Schmid
U. Kotowski
D. Thurnher, M. D.
Publication date: 01-05-2014
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 5/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0600-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines

Abstract

Background

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2014

Protection of quality and innovation in radiation oncology: The prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study)

Vergleich unterschiedlicher Fraktionierungen bei der Rebestrahlung schmerzhafter Knochenmetastasen

Rebestrahlung von schmerzhaften Knochenmetastasen

Accelerated partial breast irradiation with external beam three-dimensional conformal radiotherapy

Using fiducial markers in the prostate bed in postprostatectomy external beam radiation therapy improves accuracy over surgical clips

Long-term results of total body irradiation in adults with acute lymphoblastic leukemia